News
Dealbreaker on MSN14h
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion Deal
In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...
InvestorsHub on MSN21h
GSK shares rise after FDA grants priority review for oral gonorrhea antibiotic
GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback